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| INTRODUC TI ON
Ovarian cancer (OC) is a common gynecological disease. In Japan, the number of patients affected with ovarian cancer exceeded 10 000 in 2014 and the cumulative mortality risk of OC was 1 in 198 cases. 1 Detecting OC in the early stages is difficult due to lack of obvious symptoms. Therefore, postoperative chemotherapy is required in many cases, but outcomes are not always favorable. A global surveillance of cancer survival conducted between 2010 and 2014 concluded that the 5-year survival rate was <50% in diagnosed cases of OC in most countries. 2 Interleukin-17 (IL-17) is a pro-inflammatory cytokine produced by the cluster of differentiation 4 + (CD4 + ) helper T cells (Th17), which differ from the Th1 cells that produce interferon-γ (IFN-γ) or Th2 cells that produce IL-4. 3 Stimulation by IL-6 and transforming growth factor β (TGF-β) induces Th17 differentiation of the naïve T cells. 4 IL-17 signal transduction activates and promotes migration of neutrophils, macrophages and monocytes, which play important roles in host defense against bacterial infection. 5, 6 Th17 cells induce inflammation and are implicated in autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and asthma, 7 while also contributing to host defense against pathogens. IL-6, IL-23, IL-27, retinoic acid receptor-related orphan receptor-γt (ROR-γt) and IFN-γ are important for inducing and maintaining Th17 populations. IL-6 and TGF-β activate signal transducer and activator of transcription 3 (STAT3); this upregulates RORγt, a transcription factor that induces differentiation of the naïve T cells into Th17 cells. ROR-γt also activates the IL-23 receptor on Th17 cells. These differentiation processes are inhibited by IFN-γ and IL-27. [7] [8] [9] Tumor formation was reportedly enhanced in an IL-17-dependent manner in mice inoculated with Bacteroides fragilis, a human-resident bacterium. 10 γδT cells are another type of T cell that produce IL-17 (γδT17).
These cells were first reported in pulmonary infection by Mycobacterium tuberculosis 11 and are now known to play important roles in host defense against infection. However, γδT17 differ from Th17 cells in that they recognize non-peptide antigens independent of human leukocyte antigen molecules and antigen-presenting cells. 12 Although IL-17/Th17 expression has been confirmed in various human tumors including OC, [13] [14] [15] [16] the significance of this observation is still debated. 17 The capacity for immunosuppression is altered in cancer patients. Normally, the T cell response is initiated by recognition by the T cell receptor of an antigen expressed on a major histocompatibility complex. The action of T cells is positively or negatively regulated by co-stimulatory molecules such as CD28, which causes T cell activation, and cytotoxic T lymphocyte-associated antigen 4, which suppresses T cell function by binding to the same ligands (ie, CD80 or CD86). 18 The programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) pathway inhibits T cell activation against tumors; blockade of PD-1/PD-L1 signaling leads to antitumor efficacy in melanoma, non-small-cell lung cancer and renal-cell carcinoma. 19 However, identifying patients who may benefit from such inhibitory drugs remains challenging due to lack of appropriate biomarkers. PD-L1 is known to be highly expressed under inflammatory conditions, such as in the presence of IFN-γ. PD-L1 is also upregulated through STAT3 signaling initiated by IL-6, a major pro-inflammatory cytokine. 20, 21 We speculated that factors related to IL-17/Th17 and PD-L1 may be involved in the immune response caused by inflammation.
In fact, IL-17 has reportedly been positively associated with PD-L1 upregulation in colon and breast cancers, 22 but IL-17-PD-L1 correlation in OC has not been studied. We aimed to investigate the changes in IL-17 expression and Th17 numbers in gynecological cancer, especially in OC, and to clarify their roles in regulating PD-L1 expression. as stage I (n = 6), stage II (n = 2), stage III (n = 5) and stage IV (n = 17). Peripheral blood and tumor samples were obtained from all gynecological cancer patients. Women in the healthy control (HC) group, who ranged in age from 24 to 79 years (mean age = 50 years, n = 18), voluntarily provided peripheral blood samples. All participants provided informed consent. Patients' and tumor characteristics are listed in Table 1 .
| MATERIAL S AND ME THODS

| Patients and tissue samples
| Preparation of plasma and PBMC
Peripheral blood (20 mL) was collected from patients or HC and divided into 2 parts. Using the first part, plasma was separated and stored at −80°C immediately after centrifugation to determine cytokine levels by ELISA. PBMC were isolated from the other half of each blood sample using Ficoll Hypaque (Sigma-Aldrich) 23 and stored at −80°C for RNA extraction or stimulation. 
| Cell culture and stimulation
| Flow cytometry
PBMC suspended in 2 mL of RPMI-1640 were incubated for 4 hours at 37°C with PMA (25 ng/mL; Sigma-Aldrich) and ionomycin (1 μg/mL; Sigma-Aldrich) in the presence of 2 μL Golgi Stop (BD Biosciences).
Cells were washed and incubated in fixation and permeabilization buffers (Thermo Fisher Scientific) 8 and then labeled with the following Ab: fluorescein isothiocyanate-conjugated anti-γδT (isotype mIgG1; test IO; IM1571U), phycoerythrin-conjugated anti-CD3 (isotype mIgG1; Beckman Coulter; IM1282) and anti-CD4 (isotype mIGg1κ, PerCP5.5, BD Biosciences; 560650) were used for cell-surface labeling; and anti-IL-17 conjugated with Alexa Fluor 647 (isotype mIgG1κ; BD Biosciences; 560490) was used for intracellular labeling. At least 30 000 events were recorded using a FACSCalibur flow cytometer (BD Biosciences) and analyzed using Kaluza software (Beckman Coulter). Sigma-Aldrich. The ratio of each gene product to GAPDH was used to determine mRNA expression according to the cycle-threshold method.
| RNA isolation and quantitative RT-PCR
| Plasma cytokine measurement
Interleukin-17, IL-23 and IL-6 concentrations in plasma samples from study subjects or cell-culture supernates were measured by ELISA (Bio-Techne for IL-17; BioLegend and Bio-Techne for IL-23; and Thermo Fisher Scientific for IL-6) according to the manufacturers' instructions. 
| Western blotting
| Neutrophil-to-lymphocyte ratio
Preoperative leukocyte counts were documented by reviewing clinical charts and were used to calculate neutrophil-to-lymphocyte ratio (NLR) by dividing neutrophil count (%) by lymphocyte count (%).
| Statistical analyses
Differences between groups were evaluated using the non-para- 
| RE SULTS
| Th17 and γδT17 cell counts were elevated in ovarian cancer and endometrial cancer patients
We collected blood samples from HC, OC, endometrial cancer and cervical cancer patients and isolated PBMC, which were then stimulated with PMA and ionomycin before adding Golgi Stop and incubating at 37°C for 4 hours. CD3 + cells were identified among lymphocytes; of these, CD4 + and IL-17 + cells were identified as Th17
( Figure 1A) . Among γδT + cells, those that were IL-17 + were identified as γδT17 cells. Th17 and γδT17 counts in PBMC from each subject were used to calculate the occupancy ratios of Th17 to CD4 + cells and of γδT17 to γδT + cells, respectively. Both ratios were significantly higher in OC and endometrial cancer patients than in HC ( Figure 1B) ; however, no differences were observed between cervical cancer patients and HC. The Th17 and γδT17 occupancy were positively correlated in OC patients ( Figure 1C ).
| Th17-associated cytokines were elevated in PBMC but not in plasma of ovarian cancer patients
The PBMC mRNA levels of IL-23, ROR-γt, TNF-α, IFN-γ, IL-6 and IL-17 (factors associated with differentiation of the Th17 cells from the naïve T cells) were analyzed by qRT-PCR. We also examined the PD-L1 transcript expression to determine the relevance of these factors.
IL-17 and IL-23 were upregulated in OC patients as compared to HC, with a positive correlation observed between their expression levels (Figure 2A,B) . Levels of PD-L1, IL-6, IL-27, TNF-α, ROR-γt and IFN-γ mRNA did not differ between OC patients and HC. However, IL-17
mRNA expression correlated positively with that of the upstream factor ROR-γt, whereas IL-23 transcript level correlated positively with that of TNF-α produced by Th17 cells ( Figure 2C ). Plasma concentrations of IL-17, IL-23 and IL-6 were similar between OC patients and HC, as determined by ELISA ( Figure 2D ).
| Th17-associated cytokines were elevated in patients who received chemotherapy
To assess the effect of chemotherapy, IL-17, IL-23 and ROR-γt mRNA levels were compared in PBMC of patients who underwent surgery without chemotherapy and those who underwent interval debulking surgery (IDS) after chemotherapy. All of these factors were upregulated in patients who received chemotherapy as compared to those who did not ( Figure 2E ). The chemotherapy consisted of a combination of paclitaxel and carboplatin for all IDS cases.
| Th17 and γδT17 cell counts were elevated in mucinous carcinoma of ovarian cancer patients
We examined whether the histopathological types of OC affect the occupancy ratio of the Th17 and γδT17 cells in PBMC and found that all histopathological types of OC showed increased Th17 occupancy ratios relative to HC, whereas for γδT17, the serous and mucinous carcinoma subtypes differed from HC. In addition, the occupancy ratio of γδT17 cells in PBMC of mucinous carcinoma patients was higher than that of serous carcinoma patients ( Figure 3A ).
| Programmed death ligand 1, interleukin-6 and phospho-signal transducer and activator of transcription 3 were induced by interleukin-17A in mucinous carcinoma cells
Surgical specimens from OC patients were analyzed for IL-17A and PD-L1 expression by immunohistochemistry. Both serous and mucinous carcinoma specimens were immunopositive for IL-17A and PD-L1, with the former highly expressed in T lymphocyte ( Figure 3B ). Based on these observations, we investigated the relationship between IL-17A and PD-L1 expression using OVSAHO serous carcinoma and MCAS mucinous carcinoma cells stimulated with recombinant IL-17A. PD-L1 expression was examined after 4, 16 and 24 hours. In OVSAHO cells, IL-17A did not induce PD-L1 expression, but in MCAS cells, high levels of PD-L1 were detected at 16 and 24 hours ( Figure 3C ). As mentioned above, IL-17 expression requires IL-6 activation and STAT3 phosphorylation and activation, which are also associated with PD-L1 expression. To investigate the interaction between IL-17, IL-6, STAT3 and PD-L1, MCAS cells were stimulated with IL-17A and the concentration of each factor in the supernates was measured by ELISA. IL-6 expression ( Figure 3D ) and STAT3 phosphorylation ( Figure 3E ) were markedly altered 24 hours after IL-17A treatment.
| Interleukin-6, phospho-signal transducer and activator of transcription 3 and nuclear factor κB inhibition suppressed programmed death 1 ligand 1 expression induced by interleukin-17A
To investigate the relationship between PD-L1 expression and IL-17Ainduced IL-6 and pSTAT3 upregulation, we evaluated PD-L1 levels in IL-17A-stimulated cells treated with inhibitors of IL-6 and pSTAT3.
Application of a blocking mAb against IL-6 (mAbIL-6) abolished PD-L1 expression even in the presence of IL-17A ( Figure 4A ), although the Ab had no effect in unstimulated cells. BAY11-7082 does not directly inhibit IL-6 but abolishes NF-κB binding to DNA and thereby blocks IL-6 expression. MCAS cells stimulated with IL-17A and treated with BAY11-7082 showed decreased expression of PD-L1 24 hours later ( Figure 4B ), while DMSO did not reduce PD-L1 expression. Similarly, application of STAT3 inhibitor (S31-201) reduced STAT3 phosphorylation in IL-17A-stimulated cells in a concentration-dependent manner ( Figure 4C ) and reduced the PD-L1 protein level. qRT-PCR analysis of IL-6 and PD-L1 mRNA expression in PBMC of OC patients showed that IL-6 and PD-L1 were positively correlated ( Figure 4D ). Furthermore, plasma IL-6 concentration in OC patients correlated with the Th17 occupancy ratio in PBMC ( Figure 4E ).
| Neutrophil-to-lymphocyte ratio is positively correlated with Th17 counts in PBMC and with plasma interleukin-6 of ovarian cancer patients
We determined the NLR of OC patients immediately before surgery and found that the occupancy ratio of Th17 to CD4 + cells in PBMC ( Figure 4F ) and plasma IL-6 concentration ( Figure 4G ) positively and significantly correlated with NLR in OC patients. 
| D ISCUSS I ON
Previous studies have reported elevated Th17 counts in various cancers, including acute myeloid leukemia, 24 hepatocellular carcinoma, 25 breast cancer 15 and gallbladder cancer, 23 The IL-17 mRNA level was upregulated in OC patients compared to HC. In addition, the mRNA expression of IL-23, which is required for Th17 maintenance and proliferation, was increased and positively correlated with that of IL-17. In contrast, plasma IL-17 concentration was unaltered. This is presumably because protein production is mainly controlled at the translation stage and is not dictated by the amount of transcript. 29 However, immunohistochemistry of tumor specimens clearly showed increased expression of IL-17 in OC. Our loop. 35 We found that treatment with NF-κB inhibitor abolished IL-17-induced PD-L1 expression. Given that IL-17 activates NF-κB, then IL-17 causes PD-L1 expression by activating NF-κB, which produces IL-6 and phosphorylates STAT3 in tumor cells.
Notably, mRNA levels of IL-17 and associated factors were upregulated in the plasma of OC patients after chemotherapy.
Paclitaxel has been shown to induce PD-L1 overexpression via NF-κB activation in OC; 28, 36 our results showed that IL-17 caused an effect similar to paclitaxel; that is, it induced PD-L1 expression via NF-κB activation. Upregulation of IL-17 and associated factors in PBMC of OC patients who received chemotherapy including paclitaxel does not contradict these findings because these pathways could further stimulate IL-17 production through a feedback mechanism ( Figure 5 ).
Next, we will discuss the potential functions of STAT3 in T cell differentiation. Regulatory T cells (Treg) also differentiate from naïve T cells and maintain peripheral tolerance. Foxp3, which is essential for development and maintenance of Treg in the immune periphery, is induced also by TGF-β and IL-2 through STAT5-dependent and STAT3-dependent mechanisms. [37] [38] [39] The Foxp3 promoter contains STAT3-binding domains through which IL-6 can attenuate Foxp3 expression under inflammatory conditions. 37 Differentiation of Th17 and Treg are reportedly modified by the balance between active STAT3 and STAT5. [40] [41] [42] That is, naïve T cells are likely to differentiate into Treg when STAT5 expression is increased, while suppressing STAT3 expression. Importantly, IL-6 expression alters the balance between active STAT3 and STAT5, suppresses differentiation of the naïve T cells into Treg, and promotes naïve T cell differentiation into Th17. Treg numbers have been reported to be significantly higher in peripheral circulation of OC patients than that in healthy individuals. 43 High Th17 occupancy ratio in PBMC of OC patients suggests that high STAT3 levels are not always observed in peripheral blood of OC patients. In contrast, pSTAT3 has been reported to be expressed in OC tissues more strongly than ovarian samples from healthy individuals; pSTAT3 expression level was found by immunohistochemistry to be increased in advanced compared to early cancers. [44] [45] [46] In addition, pSTAT3 expression level was found to be F I G U R E 5 Interleukin-6 (IL-6) and transforming growth factor beta (TGF-β) phosphorylate STAT3 in naïve T cells. Naïve T cells are induced to differentiate into regulatory T cells by TGF-β in the absence of IL-6. ROR-γt is activated to induce differentiation of the naïve T cells into Th17 cells, which produce IL-17 and TNF-α. Nuclear factor-κB (NF-κB) activated by IL-17 or TNF-α stimulation induces expression of IL-6, which phosphorylates STAT3 in cancer cells. These steps result in programmed cell death 1 ligand 1 (PD-L1) expression in ovarian cancer (OC) cells and reactivation of IL-6 and STAT3 through a positive feedback loop significantly higher in chemo-resistant OC cells in vivo. 47 This suggests that high numbers of Th17 cells do not always correlate with high STAT3 levels in peripheral blood; however, the tumorigenic STAT3 activity may contribute to high numbers of Th17 cells in OC patients ( Figure 5 ).
Based on our results, we propose that the following changes occur in OC patients. IL-6 and TGF-β phosphorylate STAT3 in the naïve T cells, while ROR-γt is activated to induce differentiation of the naïve T cells into Th17 cells, which then produce IL-17 and TNF-α, thereby eliciting an inflammatory response in patients. NF-κB activation by IL-17 or TNF-α stimulation promotes IL-6, which phosphorylates STAT3; these changes induce PD-L1 expression in OC cells while reactivating IL-6 and STAT3 by feedback ( Figure 5 ).
In conclusion, elevation of Th17/IL-17, which is correlated with NLR or stimulates PD-L1, is a potential biomarker for predicting prognosis and PD-L1 overexpression in OC patients.
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